Based on the GH response to ITT < or ≥6 μg/L at retesting, 51 patients (52.6% of the entire cohort) showed a GH peak ≥6 μg/L; 2% (n = 1) belonged to the OS-GHD group, 19.6% (n = 10) to the OM-GHD group, and 78.4% (n = 40) to the I-GHD group. This evidence concerns the gene GH1 and ocular melanoma.